Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma

Clinical Cancer Research

Volumn 12, Issue 7 II, 2006, Pages

  Panka, David J ^a   Atkins, Michael B ^a   Mier, James W ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIM PROTEIN; FIBROBLAST GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN BAD; PROTEIN BCL 2; SCATTER FACTOR; SORAFENIB;

APOPTOSIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; SKIN NEOPLASMS;

EID: 33646261668     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2539     Document Type: Review

References (30)

1. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104:527-32.
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
3. Rajagopalan H, Bardelli A, Langauer C, et al. Tumorigenesis: RAF.RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
4. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
5. Alsina J, Gorsk DH, Germino FJ, et al. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Clin Cancer Res 2003;9:6419-25.
6. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
7. Cruz J, Reis-Filho JS, Silva P, Lopes JM. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology 2003;65:72-82.
8. Recio JA, Merlino G. Hepatoscyte growth factor/ scatter factor activates proliferation in melanoma cells through p38, MARK, ATF-2, and cyclin D1. Oncogene 2002;21:1000-8.
9. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff A-K. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 2004;64: 5186-92.
10. Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998;92:253-63.
11. Lo TL, Yusoff P, Fong CW, et al. The Ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, Sprouty 1 and Sprouty 2 are deregulated in breast cancer. Cancer Res 2004; 64:6127-36.
12. Sasaki A, Taketomi T, Kato R, et al. Mammalian Sprouty 4 suppresses Ras-independent ERK activation by binding to Raf1. Nat Cell Biol 2003;5:427-32.
13. Tsavachidou D, Coleman ML, Athanasiadis G, et al. SPRY2 is an inhibitor of the Ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild type BRAF but not with the V599E mutant. Cancer Res 2004;64:5556-9.
14. V599E in human melanoma abrogates transformation. Cancer Res 2003;64:5198-202.
15. Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo H-M. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein Bad. Cancer Res 2003;63:8330-7.
16. Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 2003;63:5669-73.
17. Wilhelm SM, Carter C, Tang LY, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
18. L. Cell 1996;87:619-28.
19. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003;39:615-47.
20. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003;278:18811-6.
21. Harada H, Quearry B, Ruiz-Vela A, Korsemeyer SJ. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci U S A 2004;101:15313-7.
22. Panka DJ, Atkins MB, Mier JW. BAY 43-9006 induces apoptosis in melanoma cell lines. Proc Am Assoc Cancer Res 2005. Abstract 5328.
23. Yamaguchi O, Watanabe T, Nishida K, et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 2004;114:937-43.
24. O'Neill E, Rushworth L, Baccarini M, Kolch W. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 2004;306:2267-70.
25. Lin JH, Makris A, McMahon C, et al. The ankyrin repeat-containing adaptor protein Tvl-1 is a novel substrate and regulator of Raf-1. J Biol Chem 1999;274:14706-15.
26. Huser M, Luckett J, Chiloeches A, et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J 2001;20:1940-51.
27. Hindley A, Kolch W. Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J Cell Sci 2002;115:1575-81.
28. O'Neill EE, Matallanas D, Kolch W. Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. Cancer Res 2005;65:5485-7.
29. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404-7.
30. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599E B-Raf regulates growth and vascular development of malignant tumors. Cancer Res 2005;65:2412-21.